Progress in Alzheimer's disease

Journal of Neurology

Volumn 259, Issue 2, 2012, Pages 201-211

  Galimberti, Daniela ^a   Scarpini, Elio ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Alzheimer's disease; Amyloid; Biomarkers; Diagnosis; Disease modifying drugs; Genetics; Inflammation; Tau

Indexed keywords

AMYLOID; AMYLOID BETA PROTEIN[1-42]; AVAGACESTAT; AZD 103; BAPINEUZUMAB; BIOLOGICAL MARKER; CAD 106; CLIOQUINOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DONEPEZIL; GALANTAMINE; GAMMA SECRETASE; GANTENERUMAB; GSK 933776 A; HOMOTAURINE; IMMUNOGLOBULIN G; MABT 5102 A; MEMANTINE; METHYLENE BLUE; NONSTEROID ANTIINFLAMMATORY AGENT; NOOTROPIC AGENT; PBT 1; PLACEBO; PONEZUMAB; REMBER; RIVASTIGMINE; SOLANEZUMAB; TACRINE; TARENFLURBIL; TAU PROTEIN; UNCLASSIFIED DRUG; V 950; VANUTIDE CRIDIFICAR; VARENICLINE;

ALZHEIMER DISEASE; ANOREXIA; CONFUSION; DIAGNOSTIC PROCEDURE; DIARRHEA; DIZZINESS; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME INHIBITION; HEADACHE; HUMAN; LIVER TOXICITY; NAUSEA; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REVIEW; VACCINATION; VOMITING;

ALZHEIMER DISEASE; ANIMALS; BIOLOGICAL MARKERS; EARLY DIAGNOSIS; HUMANS;

EID: 84856723844     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-011-6145-3     Document Type: Review

References (78)

1. WS Griffin 2006 Inflammation and neurodegenerative diseases Am J Clin Nutr 3 suppl 470S 474S
2. D Galimberti C Fenoglio E Scarpini 2008 Inflammation in neurodegenerative disorders: friend or foe? Curr Aging Sci 1 1 30 41 20021370 10.2174/1874609810801010030 1:CAS:528:DC%2BD1cXnsFWku70%3D
3. VP Reddy X Zhu G Perry MA Smith 2009 Oxidative stress in diabetes and Alzheimer's disease J Alzheimers Dis 16 4 763 774 19387111
4. PA Adlard AI Bush 2006 Metals and Alzheimer's disease J Alzheimers Dis 10 2-3 145 163 17119284
5. RX Santos SC Correia X Wang G Perry MA Smith PI Moreira X Zhu 2010 Alzheimer's disease: diverse aspects of mitochondrial malfunctioning Int J Clin Exp Pathol 3 6 570 581 20661404 1:CAS:528:DC%2BC3cXptFagtbw%3D
6. SW Pimplikar RA Nixon NK Robakis J Shen LH Tsai 2010 Amyloid-independent mechanisms in Alzheimer's disease pathogenesis J Neurosci 30 45 14946 14954 21068297 10.1523/JNEUROSCI.4305-10.2010 1:CAS:528:DC%2BC3cXhsV2nurvP
7. D Goldgaber MI Lerman OW McBride U Saffiotti DC Gajdusek 1987 Characterization and chromosomal localization of a cDNA encoding brain amyloid of Alzheimer's disease Science 235 4791 877 880 3810169 10.1126/science.3810169 1:CAS:528:DyaL2sXhtlaru70%3D
8. NK Robakis N Ramakrishna G Wolfe HM Wisniewski 1987 Molecular cloning and characterization of a cDNA encoding the cerebrovascular and the neuritic plaque amyloid peptides Proc Natl Acad Sci USA 84 12 4190 4194 3035574 10.1073/pnas.84.12.4190 1:CAS:528:DyaL2sXkslWqsbY%3D
9. RE Tanzi JF Gusella PC Watkins GA Bruns P St George-Hyslop ML Van Keuren, et al. 1987 Amyloid beta protein gene: cDNA, mRNA distribution, and genetic linkage near the Alzheimer locus Science 235 4791 880 884 2949367 10.1126/science.2949367 1:CAS:528:DyaL2sXhtlaru7o%3D
10. R Vassar 2004 BACE1: the beta-secretase enzyme in Alzheimer's disease J Mol Neurosci 23 1-2 105 114 15126696 10.1385/JMN:23:1-2:105 1:CAS:528: DC%2BD2cXks12jtr4%3D
11. TM Allinson ET Parkin AJ Turner NM Hooper 2003 ADAMs family members as amyloid precursor protein alpha-secretases J Neurosci Res 74 3 342 352 14598310 10.1002/jnr.10737 1:CAS:528:DC%2BD3sXptFWntr0%3D
12. D Edbauer E Winkler JT Regula B Pesold H Steiner C Haass 2003 Reconstitution of gamma-secretase activity Nat Cell Biol 5 5 486 488 12679784 10.1038/ncb960 1:CAS:528:DC%2BD3sXjtlamu70%3D
13. L Crews E Masliah 2010 Molecular mechanisms of neurodegeneration in Alzheimer's disease Hum Mol Genet 19 1 R12 R20 20413653 10.1093/hmg/ddq160 1:CAS:528:DC%2BC3cXmsVSrtL4%3D
14. RJ Castellani A Nunomura H Lee G Perry MA Smith 2008 Phosphorylated tau: toxic, protective, or none of the above J Alzheimers Dis 14 377 383 18688087
15. CRJ Jack Jr DS Knopman WJ Jagust LM Shaw PS Aisen MW Weiner, et al. 2010 Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade Lancet Neurol 9 119 128 20083042 10.1016/S1474-4422(09)70299-6 1:CAS:528:DC%2BC3cXhtFeru74%3D
16. G McKhann D Drachman M Folstein R Katzman D Price EM Stadlan 1984 Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease Neurology 34 939 944 6610841 1:STN:280:DyaL2c3ks1altQ%3D%3D
17. B Dubois HH Feldman C Jacova ST Dekosky P Barberger-Gateau J Cummings, et al. 2007 Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria Lancet Neurol 6 8 734 746 17616482 10.1016/S1474-4422(07)70178-3
18. RC Petersen GE Smith SC Waring RJ Ivnik EG Tangalos E Kokmen 1999 Mild cognitive impairment: clinical characterization and outcome Arch Neurol 56 3 303 308 10190820 10.1001/archneur.56.3.303 1:STN:280:DyaK1M3gsFSqtw%3D%3D
19. FH Bouwman NA Verwey M Klein A Kok MA Blankenstein JD Sluimer, et al. 2010 New research criteria for the diagnosis of Alzheimer's disease applied in a memory clinic population Dement Geriatr Cogn Disord 30 1 1 7 20606438 10.1159/000315542 1:STN:280:DC%2BC3cfgtVyqsg%3D%3D
20. CA de Jager TE Honey J Birks GK Wilcock 2010 Retrospective evaluation of revised criteria for the diagnosis of Alzheimer's disease using a cohort with post-mortem diagnosis Int J Geriatr Psychiatry 25 10 988 997 20217711 10.1002/gps.2448
21. GB Frisoni S Galluzzi M Signorini V Garibotto B Paghera G Binetti, et al. 2010 Preliminary evidence of validity of the revised criteria for Alzheimer disease diagnosis: report of 2 cases Alzheimer Dis Assoc Disord 24 1 108 114 19568153 10.1097/WAD.0b013e3181a1fd34
22. B Dubois HH Feldman C Jacova JL Cummings ST Dekosky P Barberger-Gateau, et al. 2010 Revising the definition of Alzheimer's disease: a new lexicon Lancet Neurol 9 11 1118 1127 20934914 10.1016/S1474-4422(10)70223-4
23. RJ Jack Jr MS Albert DS Knopman GM McKhann RA Sperling MC Carrillo, et al. 2011 Introduction to the recommendations from the National Institute on Aging and the Alzheimer's Association workgroup on diagnostic guidelines for Alzheimer's disease Alzheimers Dement 7 3 257 262 21514247 10.1016/j.jalz.2011. 03.004
24. GM McKhann DS Knopman H Chertkow BT Hyman CR Jack Jr CH Kawas, et al. 2011 The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging and the Alzheimer's Association workgroup Alzheimers Dement 7 3 263 269 21514250 10.1016/j.jalz.2011.03.005
25. MS Albert ST DeKosky D Dickson B Dubois HH Feldman NC Fox, et al. 2011 The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging and Alzheimer's Association workgroup Alzheimers Dement 7 3 270 279 21514249 10.1016/j.jalz.2011.03.008
26. RA Sperling PS Aisen LA Beckett DA Bennett S Craft AM Fagan, et al. 2011 Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging and the Alzheimer's Association workgroup Alzheimers Dement 7 3 280 292 21514248 10.1016/j.jalz.2011.03.003
27. AD Lawrence BJ Sahakian 1998 The cognitive psychopharmacology of Alzheimer's disease: focus on cholinergic systems Neurochem Res 23 5 787 794 9566619 10.1023/A:1022419712453 1:CAS:528:DyaK1cXisV2rt7k%3D
28. M Farlow 2002 A clinical overview of cholinesterase inhibitors in Alzheimer's disease Int Psychogeriatr/IPA 14 Suppl.1 93 126 10.1017/ S1041610203008688
29. C Courtney D Farrell R Gray R Hills L Lynch E Sellwood, et al. 2004 Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial Lancet 363 9427 2105 2115 15220031 10.1016/S0140-6736(04)16499-4 1:STN:280:DC%2BD2czhvFCqsQ%3D%3D
30. J Birks 2006 Cholinesterase inhibitors for Alzheimer's disease Cochrane Database Syst Rev 1 CD005593 16437532
31. P Raina P Santaguida A Ismaila C Patterson D Cowan M Levine, et al. 2008 Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline Ann Intern Med 148 5 379 397 18316756
32. G Alva JL Cummings 2008 Relative tolerability of Alzheimer's disease treatments Psychiatry (Edgmont) 5 11 27 36
33. Scarpini E, Scheltens P, Feldman H (2003) Treatment of Alzheimer's disease: current status and new perspectives. Lancet Neurol 2(9):539-547
34. F Gervais R Chalifour D Garceau X Kong J Laurin R Mclaughlin, et al. 2001 Glycosaminoglycan mimetics: a therapeutic approach to cerebral amyloid angiopathy Amyloid 8 Suppl.1 28 35 11676287 1:CAS:528:DC%2BD3MXnvVCltL0%3D
35. PS Aisen D Saumier R Briand J Laurin F Gervais P Tremblay, et al. 2006 A phase II study targeting amyloid-beta with 3APS in mild-to-moderate Alzheimer disease Neurology 67 10 1757 1763 17082468 10.1212/01.wnl.0000244346.08950.64 1:CAS:528:DC%2BD28Xht1SjsLzN
36. D Galimberti E Scarpini 2011 Alzheimer's disease: from pathogenesis to disease-modifying approaches CNS Neurol Disord Drug Targets 10 2 163 174 21222635 1:CAS:528:DC%2BC3MXislajtL0%3D
37. I Santa-Maria F Hernández J Del Rio FJ Moreno J Avila 2007 Tramiprosate, a drug of potential interest for the treatment of Alzheimer's disease, promotes an abnormal aggregation of tau Mol Neurodegener 2 1 17 17822548 10.1186/1750-1326-2-17
38. J Leszek AD Inglot M Janusz J Lisowski K Krukowska JA Georgiades 1999 Colostrinin: a proline-rich polypeptide (PRP) complex isolated from ovine colostrum for treatment of Alzheimer's disease. A double-blind, placebo-controlled study Arch Immunol Ther Exp (Warsz) 47 6 377 385 1:CAS:528:DC%2BD3cXhvFCktbs%3D
39. A Bilikiewicz W Gaus 2004 Colostrinin (a naturally occurring, proline-rich, polypeptide mixture) in the treatment of Alzheimer's disease J Alzheimer's Dis 6 17 26 1:CAS:528:DC%2BD2cXhsleksbc%3D
40. KP Townsend D Praticò 2005 Novel therapeutic opportunities for Alzheimer's disease: focus on nonsteroidal anti-inflammatory drugs FASEB J 19 12 1592 1601 16195368 10.1096/fj.04-3620rev 1:CAS:528:DC%2BD2MXhtV2nu7rJ
41. D Schenk R Barbour W Dunn 1999 Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in PDAPP mouse Nature 400 173 177 10408445 10.1038/22124 1:CAS:528:DyaK1MXks1Khsbc%3D
42. S Gilman M Koller RS Black 2005 Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial Neurology 64 1553 1562 15883316 10.1212/01.WNL.0000159740.16984.3C 1:CAS:528:DC%2BD2MXjsVCjsbg%3D
43. 42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial Lancet 372 216 223 18640458 10.1016/S0140-6736(08)61075-2 1:CAS:528:DC%2BD1cXoslWkt74%3D
44. Grundman M, Black R (2008) Clinical trials of bapineuzumab, a beta-amyloid targeted immunotherapy in patients with mild to moderate Alzheimer's disease. Alzheimers Dement 4(Suppl.2):T166
45. JO Rinne DJ Brooks MN Rossor NC Fox R Bullock WE Klunk, et al. 2010 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study Lancet Neurol 9 4 363 372 20189881 10.1016/S1474-4422(10)70043-0 1:CAS:528:DC%2BC3cXltF2kt7Y%3D
46. R Dodel F Neff C Noelker R Pul Y Du M Bacher, et al. 2010 Intravenous immunoglobulins as a treatment for Alzheimer's disease: rationale and current evidence Drugs 70 5 513 528 20329802 10.2165/11533070-000000000-00000 1:CAS:528:DC%2BC3cXmt1egtr4%3D
47. S Weggen JL Eriksen P Das SA Sagi R Wang CU Pietrzik, et al. 2001 A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity Nature 414 6860 212 216 11700559 10.1038/35102591 1:CAS:528: DC%2BD3MXosFahsLc%3D
48. D Beher EE Clarke JD Wrigley AC Martin A Nadin I Churcher, et al. 2004 Selected nonsteroidal anti-inflammatory drugs and their derivatives target γ-secretase at a novel site: evidence for an allosteric mechanism J Biol Chem 279 43419 43426 15304503 10.1074/jbc.M404937200 1:CAS:528: DC%2BD2cXot1yhtL4%3D
49. T Kukar S Prescott JL Eriksen V Holloway MP Murphy EH Koo, et al. 2007 Chronic administration of R-flurbiprofen attenuates learning impairments in transgenic amyloid precursor protein mice BMC Neurosci 8 54 17650315 10.1186/1471-2202-8-54
50. DR Galasko N Graff-Radford S May S Hendrix BA Cottrell SA Sagi, et al. 2007 Safety, tolerability, pharmacokinetics, and Aβ levels after short-term administration of R-flurbiprofen in healthy elderly individuals Alzheimer Dis Assoc Disord 21 4 292 299 18090435 10.1097/WAD.0b013e31815d1048 1:CAS:528:DC%2BD1cXjsValsQ%3D%3D
51. GK Wilcock SE Black SB Hendrix KH Zavitz EA Swabb MA Laughlin, et al. 2008 Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial Lancet Neurol 7 6 483 493 18450517 10.1016/S1474-4422(08)70090-5 1:CAS:528:DC%2BD1cXntlSjtL8%3D
52. SJ Pollack H Lewis 2005 Secretase inhibitors for Alzheimer's disease: challenges of promiscuous protease Curr Opin Investig Drugs 6 35 47 15675602 1:CAS:528:DC%2BD2MXht1KktL8%3D
53. GT Wong D Manfra FM Poulet Q Zhang H Josien T Bara, et al. 2004 Chronic treatment with the γ-secretase inhibitor LY-411, 575 inhibit β-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation J Biol Chem 279 12876 12882 14709552 10.1074/jbc.M311652200 1:CAS:528:DC%2BD2cXitl2gtb0%3D
54. E Siemers M Skinner RA Dean C Gonzales J Satterwhite M Farlow, et al. 2005 Safety, tolerability, and changes in in amyloid β concentrations after administration of a γ-secretase inhibitor in volunteers Clin Neuropharmacol 28 126 132 15965311 10.1097/01.wnf.0000167360.27670.29 1:CAS:528:DC%2BD2MXltlSrurw%3D
55. ER Siemers JF Quinn J Kaye MR Farlow A Porsteinsson P Tariot, et al. 2006 Effects of a γ-secretase inhibitor in a randomized study of patients with Alzheimer disease Neurology 66 602 604 16505324 10.1212/01.WNL.0000198762. 41312.E1 1:CAS:528:DC%2BD28XhtFeis7s%3D
56. M Marcade J Bourdin N Loiseau H Peillon A Rayer D Drouin, et al. 2008 Etazolate, a neuroprotective drug linking GABA(A) receptor pharmacology to amyloid precursor protein processing J Neurochem 106 1 392 404 18397369 10.1111/j.1471-4159.2008.05396.x 1:CAS:528:DC%2BD1cXot1Ogtrc%3D
57. CM Wischik PC Edwards RY Lai M Roth CR Harrington 1996 Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines Proc Natl Acad Sci USA 93 20 11213 11218 8855335 10.1073/pnas.93.20.11213 1:CAS:528:DyaK28XmtVOqsLg%3D
58. Y Balaraman AR Limaye AI Levey S Srinivasan 2006 Glycogen synthase kinase 3β and Alzheimer's disease: pathophysiological and therapeutic significance Cell Mol Life Sci 63 1226 1235 16568235 10.1007/s00018-005-5597-y 1:CAS:528:DC%2BD28Xmslaisb8%3D
59. A Martinez DI Perez 2008 GSK-3 inhibitors: a ray of hope for the treatment of Alzheimer's disease? J Alzheimers Dis 15 181 191 18953107 1:CAS:528:DC%2BD1cXht1CmtrzF
60. A Schneider E Mandelkow 2008 Tau-based treatment strategies in neurodegenerative diseases Neurotherapeutics 5 443 457 18625456 10.1016/j.nurt.2008.05.006 1:CAS:528:DC%2BD1cXhtVOgtLrI
61. PL McGeer M Schulzer EG Mc Geer 1996 Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies Neurology 47 425 432 8757015 1:CAS:528:DyaK28Xls1Gltrw%3D
62. SA Reines GA Block JC Morris G Liu ML Nessly CR Lines, et al. 2004 Rofecoxib Protocol 091 Study Group. Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study Neurology 62 66 71 14718699 1:CAS:528:DC%2BD3sXhtVWjtrrL
63. PS Aisen KA Schafer M Grundman E Pfeiffer M Sano KL Davis, et al. 2003 Effects of rofecoxib or naproxen vs placebo on Alzheimer's disease progression: a randomized controlled trial JAMA 289 2819 2826 12783912 10.1001/jama.289.21. 2819 1:CAS:528:DC%2BD3sXktlKmsb0%3D
64. S Scharf A Mander A Ugoni F Vajda N Christophidis 1999 A double-blind, placebo controlled trial of diclofenac/misoprostol in Alzheimer's disease Neurology 53 197 201 10408559 1:CAS:528:DyaK1MXkvFCkt7w%3D
65. H Soininen C West J Robbins L Niculescu 2007 Long-term efficacy and safety of celecoxib in Alzheimer's disease Dement Geriatr Cogn Disord 23 1 8 21 17068392 10.1159/000096588 1:CAS:528:DC%2BD28XhtlSrsLvP
66. JL Eriksen SA Sagi TE Smith S Weggen P Das DC McLendon, et al. 2003 NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lowe Abeta 42 in vivo J Clin Invest 112 3 440 449 12897211 1:CAS:528:DC%2BD3sXmtFemtrY%3D
67. PS Aisen DB Marin AM Brickman J Santoro M Fusco 2001 Pilot tolerability studies of hydroxychloroquine and colchicine in Alzheimer disease Alz Dis Assoc Disord 15 2 96 101 10.1097/00002093-200104000-00009 1:CAS:528: DC%2BD3MXkslOhtrs%3D
68. PS Aisen J Schmeidler GM Pasinetti 2002 Randomized pilot study of nimesulide treatment in Alzheimer's disease Neurology 58 7 1050 1054 11940691 1:CAS:528:DC%2BD38XjtlCiu78%3D
69. J Rogers LC Kirby SR Hempelman DL Berry PL McGeer AW Kaszniak, et al. 1993 Clinical trial of indomethacin in Alzheimer's disease Neurology 43 1609 1611 8351023 1:STN:280:DyaK3szlsVGrtw%3D%3D
70. PS Aisen LS Schneider M Sano R Diaz-Arrastia CH van Dyck MF Weiner, et al. 2008 High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial JAMA 300 15 1774 1783 18854539 10.1001/jama.300.15.1774 1:CAS:528:DC%2BD1cXht1GqtLnE
71. DM Barten CF Albright 2008 Therapeutic strategies for Alzheimer's disease Mol Neurobiol 37 171 186 18581273 10.1007/s12035-008-8031-2 1:CAS:528:DC%2BD1cXptFOrur0%3D
72. AI Bush WH Pettingell G Multhaup M Paradis JP Vonsattel JF Gusella, et al. 1994 Rapid induction of Alzheimer Aβ amyloid formation by zinc Science 265 1464 1467 8073293 10.1126/science.8073293 1:CAS:528:DyaK2cXmsFaqs7k%3D
73. AI Bush 2008 Drug development based on the metals hypothesis of Alzheimer's disease J Alzheimers Dis 15 223 240 18953111 1:CAS:528: DC%2BD1cXht1Cmtr3J
74. RA Cherny CS Atwood ME Xilinas DN Gray WD Jones CA McLean, et al. 2001 Treatment with a copper-zinc chelator markedly and rapidly inhibits β-amyloid accumulation in Alzheimer's disease transgenic mice Neuron 30 665 676 11430801 10.1016/S0896-6273(01)00317-8 1:CAS:528:DC%2BD3MXkvFSksbw%3D
75. L Lannfelt K Blennow H Zetterberg S Batsman D Ames J Harrison, et al. 2008 Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomized, placebo-controlled trial Lancet Neurol 7 9 779 786 18672400 10.1016/S1474-4422(08)70167-4 1:CAS:528:DC%2BD1cXhtFWmsL3F
76. CW Ritchie AI Bush Mackinnon S Macfarlane M Mastwyk L MacGregor, et al. 2003 Metal-protein attenuation with iodochlorhydroxyquin (Clioquinol) targeting Aβ amyloid deposition and toxicity in Alzheimer disease Arch Neurol 60 1685 1691 14676042 10.1001/archneur.60.12.1685
77. L Jenagaratnam R McShane 2006 Clioquinol for the treatment of Alzheimer's disease Cochrane Database Syst Rev 25 1 CD005380
78. PS Aisen S Andrieu C Sampaio M Carrillo ZS Khachaturian B Dubois, et al. 2011 Report of the task force on designing clinical trials in early (predementia) AD Neurology 76 3 280 286 21178097 10.1212/WNL.0b013e318207b1b9 1:STN:280:DC%2BC3M7itVWhug%3D%3D